Grabher Consulting & Specialty Services, Forest Hill, Maryland
J Nucl Med Technol. 2023 Sep;51(3):188-193. doi: 10.2967/jnmt.122.265272. Epub 2023 Jul 11.
In September 2020, the published a continuing education article, "Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes," that reviewed a promising new PET tracer, 16α-F-fluoro-17β-fluoroestradiol (F-FES). This tracer had the potential to be a valuable tool for medical oncologists and breast surgeons in noninvasively evaluating the estrogen receptor site status of their patients' recurrent tumor and secondary metastatic lesions. In May 2020, F-FES received Food and Drug Administration approval and began being marketed by Zionexa using the trade name Cerianna and manufactured by PETNET. In May 2021, GE Healthcare acquired Zionexa, and Cerianna and is now being marketed by GE Healthcare and is still being manufactured by PETNET. This article will review the F-FES package insert information and imaging protocol, as well as important guidelines for imaging with F-FES.
2020 年 9 月，该杂志发表了一篇继续教育文章，题为“乳腺癌：利用分子成像评估肿瘤雌激素受体状态以提高治疗反应并改善患者预后”，该文章回顾了一种有前途的新型 PET 示踪剂 16α-F-氟-17β-氟雌二醇（F-FES）。该示踪剂有可能成为医学肿瘤学家和乳腺外科医生的有用工具，可用于非侵入性地评估其患者复发性肿瘤和继发性转移病灶的雌激素受体部位状态。2020 年 5 月，F-FES 获得美国食品和药物管理局批准，并开始由 Zionexa 使用商品名 Cerianna 进行营销，由 PETNET 制造。2021 年 5 月，GE Healthcare 收购了 Zionexa，Cerianna 现由 GE Healthcare 营销，仍由 PETNET 制造。本文将回顾 F-FES 的包装插页信息和成像方案，以及使用 F-FES 进行成像的重要指南。
